Cassava Sciences, Inc. Overview
Pro stress-test →Cassava Sciences is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer's disease and tuberous sclerosis complex (TSC)-related seizures. The company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer's disease or TSC.
Strategic Profile
Pro stress-test →Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The licensing of rights from Yale for the use of simufilam as a treatment for seizures related to rare neurodevelopmental disorders represents a noteworthy expansion of its therapeutic focus.
Competitive Landscape
Pro stress-test →Cassava competes in the clinical-stage Alzheimer's and neurodegeneration space with a research program centered on small molecules designed to address underlying mechanisms of neurodegeneration rather than solely targeting amyloid plaques or tau tangles. Competitors include other CNS-focused biotechs like Annovis Bio, Anavex Life Sciences, and larger pharma pursuing traditional amyloid-targeting approaches.
Industry Context
Cassava Sciences, Inc. operates in Clinical-Stage Biotechnology/Biopharmaceuticals (CNS/Neurodegenerative Disorders).
Key facts
Founded: 1998 · Headquarters: Austin, Texas · Employees: 30 · Revenue: N/A · Market cap: $107M